Saturday 17 October 2026
Export ALLO’s income statement to Excel — free account
Allogene Therapeutics, Inc.
ALLO Healthcare Biotechnology
Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023. In the quarter to June 2026, revenue grew 20,990.9%, EPS grew 43.5% and free cash flow grew 17.7%, each against the same quarter a year earlier.
1.31
0.03
−2.24%
Follow ALLO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(54.43%) | (53.42%) | (52.32%) | (42.39%) | |
| (41.21%) | (39.58%) | (38.45%) | (32.43%) | ||
ROIC |
(225.11%) | (309.04%) | (991.62%) | (108.81%) | |
Return on Tangible Assets |
(69.56%) | (64.04%) | (55.16%) | (44.05%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(0.72) | (0.68) | (0.46) | (0.31) | |
Free Cash Flow |
(158.99) | (149.63) | (109.53) | (102.60) | |
Capital Expenditures |
(0.64) | (0.39) | (0.30) | (0.40) | |
| Other line items | |||||
Cash ROIC |
(28.01%) | (27.57%) | (20.07%) | (13.35%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,604.04% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,327.04% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 796.85% | |
Interest Coverage |
(269.75) | (194.71) | (155.28) | (138.71) | |
Operating CF/Net income |
0.75 | 0.78 | 0.63 | 0.62 | |
Depreciation/Fixed assets |
0.10 | 0.11 | 0.12 | 0.11 | |
Capex/Depreciation |
(0.09) | (0.05) | (0.04) | (0.05) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF per Share |
(0.71) | (0.68) | (0.45) | (0.31) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.09 |
Columns are period end dates